GYRE THERAPEUTICS Trademark

Trademark Overview


On Monday, June 23, 2025, a trademark application was filed for GYRE THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the GYRE THERAPEUTICS trademark a serial number of 99248258. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, June 23, 2025. This trademark is owned by Gyre Therapeutics, Inc.. The GYRE THERAPEUTICS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for the treatment and prevention of chronic obstructive pulmonary disease, pulmonary arterial hypertension, acute liver failure, acute-on-chronic liver failure, liver fibrosis, metabolic dysfunction associated fatty liver disease, nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, lung fibrosis, organ fibrosis, and inflammatory diseases

Conducting early evaluations in the field of new pharmaceuticals; Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Testing of pharmaceuticals
gyre therapeutics

General Information


Serial Number99248258
Word MarkGYRE THERAPEUTICS
Filing DateMonday, June 23, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateMonday, June 23, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing0 - NOT AVAILABLE
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of five crescent shapes arranged to form a circle, a capsule shape resembling a pill inside the circle, the capsule having a half crescent shape cutting into the capsule, letters forming the phrase “Gyre” with the letter “G” in capital letter situated to the right of the circle, and letters forming the phrase “THERAPEUTICS” situated underneath the phrase “Gyre”.
Goods and ServicesPharmaceutical preparations for the treatment and prevention of chronic obstructive pulmonary disease, pulmonary arterial hypertension, acute liver failure, acute-on-chronic liver failure, liver fibrosis, metabolic dysfunction associated fatty liver disease, nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, lung fibrosis, organ fibrosis, and inflammatory diseases
Goods and ServicesConducting early evaluations in the field of new pharmaceuticals; Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Testing of pharmaceuticals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, June 23, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, June 23, 2025
Primary Code042
First Use Anywhere DateMonday, October 30, 2023
First Use In Commerce DateMonday, October 30, 2023

Trademark Owner History


Party NameGyre Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events


Event DateEvent Description
Monday, June 23, 2025NEW APPLICATION ENTERED
Monday, June 23, 2025APPLICATION FILING RECEIPT MAILED